导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.71% | 2987/4773 |
| 近一周 | -2.77% | 3034/5462 |
| 近一月 | -0.04% | 711/5421 |
| 近一季 | -2.15% | 1197/5209 |
| 近半年 | -6.78% | 3138/4920 |
| 近一年 | -1.59% | 2897/4366 |
| 近两年 | 35.75% | 2061/2954 |
| 近三年 | 40.73% | 704/2253 |
| 成立以来 | 27.70% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.45% 1269/4961 |
-10.48% 4112/5312 |
- - |
- - |
| 2025 | 22.26% 1983/4813 |
2.27% 1420/3635 |
9.58% 275/4076 |
5.11% 3606/4524 |
3.80% 622/4813 |
| 2024 | 21.05% 425/3463 |
-0.02% 1061/2808 |
9.23% 54/3014 |
8.34% 2753/3129 |
2.31% 962/3463 |
| 2023 | 1.20% 365/2656 |
5.66% 761/2280 |
2.79% 123/2385 |
-6.14% 1440/2515 |
-0.72% 246/2655 |
| 2022 | -1.57% 49/2207 |
-1.49% 147/1919 |
3.36% 1166/2016 |
-11.21% 507/2113 |
8.88% 250/2208 |
| 2021 | 8.31% 483/1822 |
12.59% 18/1255 |
0.21% 1108/1330 |
0.99% 460/1466 |
-4.95% 1500/1822 |
| 2020 | -21.74% 1009/1250 |
-18.02% 1001/1028 |
-0.91% 1027/1067 |
-6.91% 1129/1164 |
3.48% 911/1184 |
| 2019 | 2.99% 804/1092 |
7.34% 730/739 |
-3.89% 407/788 |
-6.71% 815/850 |
7.01% 506/918 |
| 2018 | -5.53% 61/834 |
- - |
0.44% 34/631 |
4.13% 76/660 |
-6.62% 50/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 摩根标普港股通低波红利指数C VS. 长安沪深300非周期A(740101) |